Direct-acting antivirals for HCV associated with reduced risk for mortality and HCC

Source: The Lancet - 11 Feb 2019

The Lancet has released an article which points to the positive clinical outcomes of direct-acting antiviral treatment for hepatitis C. The findings of the study mean that “treatment with direct-acting antivirals is associated with reduced risk for mortality and hepatocellular carcinoma and should be considered in all patients with chronic HCV infection”.

The article titled, Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study was authored by Prof Fabrice Carrat, PhD; Hélène Fontaine, MD; Céline Dorival, PhD; Mélanie Simony, MS; Alpha Diallo, MD; Prof Christophe Hezode, MD; et al.

You can view the summary article on The Lancet website using the button below.